Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:17187505rdf:typepubmed:Citationlld:pubmed
pubmed-article:17187505lifeskim:mentionsumls-concept:C0007226lld:lifeskim
pubmed-article:17187505lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:17187505lifeskim:mentionsumls-concept:C0031325lld:lifeskim
pubmed-article:17187505pubmed:issue1lld:pubmed
pubmed-article:17187505pubmed:dateCreated2006-12-25lld:pubmed
pubmed-article:17187505pubmed:abstractTextJohn Carlquist received a PhD from the Department of Cellular Viral and Molecular Biology at the University of Utah School of Medicine (UT, USA) with research emphasis in molecular immunology. After completion of his training, he received a faculty appointment in the Department of Internal Medicine, University of Utah, where he became interested in immune mechanisms in cardiovascular disease. He developed an interest in genetics through studies of human leukocyte antigen (HLA) associations with idiopathic dilated cardiomyopathy and rheumatic heart disease. He began the Molecular Diagnostics Laboratory for Intermountain Healthcare and continues to serve as Technical Director; he also directs the Intermountain Heart Study Molecular and Genetic Research Laboratory. Current research interests include the genetics of lipid metabolism as related to coronary heart disease and the genetic factors influencing drug treatment outcomes.lld:pubmed
pubmed-article:17187505pubmed:languageenglld:pubmed
pubmed-article:17187505pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17187505pubmed:citationSubsetIMlld:pubmed
pubmed-article:17187505pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17187505pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17187505pubmed:statusMEDLINElld:pubmed
pubmed-article:17187505pubmed:monthJanlld:pubmed
pubmed-article:17187505pubmed:issn1744-8042lld:pubmed
pubmed-article:17187505pubmed:authorpubmed-author:CarlquistJohn...lld:pubmed
pubmed-article:17187505pubmed:issnTypeElectroniclld:pubmed
pubmed-article:17187505pubmed:volume8lld:pubmed
pubmed-article:17187505pubmed:ownerNLMlld:pubmed
pubmed-article:17187505pubmed:authorsCompleteYlld:pubmed
pubmed-article:17187505pubmed:pagination21-3lld:pubmed
pubmed-article:17187505pubmed:meshHeadingpubmed-meshheading:17187505...lld:pubmed
pubmed-article:17187505pubmed:meshHeadingpubmed-meshheading:17187505...lld:pubmed
pubmed-article:17187505pubmed:meshHeadingpubmed-meshheading:17187505...lld:pubmed
pubmed-article:17187505pubmed:meshHeadingpubmed-meshheading:17187505...lld:pubmed
pubmed-article:17187505pubmed:meshHeadingpubmed-meshheading:17187505...lld:pubmed
pubmed-article:17187505pubmed:meshHeadingpubmed-meshheading:17187505...lld:pubmed
pubmed-article:17187505pubmed:year2007lld:pubmed
pubmed-article:17187505pubmed:articleTitleCardiovascular therapy and pharmacogenetics in 2007.lld:pubmed
pubmed-article:17187505pubmed:publicationTypeInterviewlld:pubmed